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SARS-CoV-2, which belongs to a unique clade of the Sarbecovirus subgenus of 
the Orthocoronavirinae subfamily, was identified as the pathogen of Coronavirus 
disease 2019 (COVID-19) in January 2020. A majority (67-85%) of critically ill 
patients admitted in intensive care units with confirmed infection of severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) developed the acute 
respiratory distress syndrome (ARDS). Indonesia has been hit by COVID-19 with 
CFR being 8.9% at the end of March 2020. There have been 1,528 confirmed 
COVID-19 cases in Indonesia and 136 deaths related to the disease. The nation’s 
case fatality rate (CFR) is also much higher than that of the People’s Republic of 
China (8.9% vs 4%). According to the latest data of the Ministry of Health of 
Indonesia, there are only 309,100 hospital beds in Indonesia, with most of them 
being located on Java island. On top of that, there is less than 6,000 Intensive Care 
Unit (ICU) beds nationwide. The number appears much, but in fact, Indonesia only 
had 2.7 ICU beds per 100,000 people and thus the country ranked among the lowest 
in Asia. Indonesia’s president finally decided to implement large-scale social 
restriction / Pembatasan Sosial Berskala Besar in cities and provinces, instead of 
regional quarantine. Regional quarantine is one of four types of health quarantine 
according to the 2018 Health Quarantine Law. The government also emphasizes 
the need to stay at home for all Indonesian citizens, and this “lockdown” scenario 
was initially prepared in Jakarta and West Java in March 2020. 
 
Keywords: COVID-19, Treatment, Case Report, North Sumatera, Indonesia 
 
Please cite this article as: Fadinie W. COVID-19 Treatment in Medan, Indonesia: a 
Case Report. J Cell Mol Anesth. 2021;6(2):192-6. DOI: 
https://doi.org/10.22037/jcma.v6i2.33927 
   
 
Introduction 
The outbreak of the “Coronavirus Disease 2019” 
(COVID-19) started in December 2019, as unknown 
pneumonia that occurred in Wuhan with a history of 
South China seafood market exposure, then quickly 
became a sweeping and unprecedented challenge to 
different stakeholders in mainland China, and later, has 
been declared a public health emergency by the World 
Health Organization on January 30, 2020 (1-3). In the 
past decades, two known zoonotic coronaviruses, 
SARS-CoV and MERS-CoV, have been reported to 
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damage the respiratory tract and cause severe outbreaks. 
Severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) is a newly discovered coronavirus, 
which was first discovered in Wuhan, China in 
December 2019 (1). Coronaviruses are enveloped, 
positive single-stranded large RNA viruses that infect 
humans, but also a wide range of animals. 
Coronaviruses were first described in 1966 by Tyrell 
and Bynoe, who cultivated the viruses from patients 
with common colds (2-4). 
SARS-CoV-2, which belongs to a unique clade 
of the Sarbecovirus subgenus of the 
Orthocoronavirinae subfamily, was identified as the 
pathogen of Coronavirus disease 2019 (COVID-19) in 
January 2020 (3). A majority (67-85%) of critically ill 
patients admitted in intensive care units with confirmed 
infection of severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) developed the acute 
respiratory distress syndrome (ARDS) (4). 
The maximum incubation period is assumed to be 
up to 14 days, whereas the median time from onset of 
symptoms to intensive care unit (ICU) admission is 
around 10 days. Recently, WHO reported that the time 
between symptom onset and death ranged from about 2 
weeks to 8 weeks (5). The severity of the patient’s 
symptoms was categorized as mild, severe, or critical. 
Mild included non-pneumonia and mild pneumonia 
cases. Severe was characterized by dyspnea, respiratory 
frequency ≥30/minute, blood oxygen saturation ≤93%, 
PaO2/FiO2ratio <300, and/or lung infiltrates >50% 
within 24–48hours. Critical cases were those that 
exhibited respiratory failure, septic shock, and/or 
multiple organ dysfunction/failure (6, 7). 
Indonesia has been hit by COVID-19 with CFR 
being 8.9% at the end of March 2020 (11). There have 
been 1,528 confirmed COVID-19 cases in Indonesia 
and 136 deaths related to the disease. The nation’s case 
fatality rate (CFR) is also much higher than that of the 
People’s Republic of China (8.9% vs 4%) (1-2). 
According to the latest data of the Ministry of 
Health of Indonesia, there are only 309,100 hospital 
beds in Indonesia, with most of them being located on 
Java island. On top of that, there is less than 6,000 
Intensive Care Unit (ICU) beds nationwide. The number 
appears much, but in fact, Indonesia only had 2.7 ICU 
beds per 100,000 people and thus the country ranked 
among the lowest in Asia (1-3). 
Indonesia’s president finally decided to 
implement large-scale social restriction / Pembatasan 
Sosial Berskala Besar in cities and provinces, instead of 
regional quarantine. Regional quarantine is one of four 
types of health quarantine according to the 2018 Health 
Quarantine Law. The government also emphasizes the 
need to stay at home for all Indonesian citizens, and this 
“lockdown” scenario was initially prepared in Jakarta 




A 48-years male presented to the ER at 15:37 with 
unconsciousness which occurs since midnight one day 
ago, with fever and respiratory distress from last week. 
Coughs were noticed three days ago. There were no 
difficulties or abnormalities in urination or defecation. 
The patient’s family denied any sore throat, 
epilepsy and denied having anti-TB drugs. History of 
cardiac disease, diabetes, hypertension was also denied. 
History of traveling outside Medan or meeting anyone 
from outside Medan was denied. History of having 
COVID-19 positive in the nearby neighborhood was 
denied. 
On clinical examinations, sopor, BP: 130/90 
mmHg, HR: 120 bpm, RR: 30 bpm with SpO2 70-75%, 
Temp: 38C. Ronchi was heard on the left lung during 
chest auscultation. This patient was then diagnosed with 
Probable COVID-19 dd/ ARDS. CHF and given initial 
therapies from the ER, as stated below: 
1. IVFD NaCl 0.9% 20 gtt 
2. Injected Dexamethasone  
3. Injected Meropenem 1 gram /8 hour 
4. Injected Levofloxacin 750 mg /24 hour  
5. Oseltamifir 75 mg/12 hour po 
6. Hidroquinon 200 mg/12 hour po 
7. Injected Vitamin C 1 gram/12-hour IV 
The lab results are stated below: 
 Hb/Ht/L/T: 11,1/34/9750/349000 
 Neutrophil: 86,9 
 Lymphocyte: 8,3 
 PT/APTT/INR: 18,3(14)/26,5(32,5)/1,35 
 D-dimer: >4000 ng/ml 
 SGOT(ALT)/SGPT(AST): 53/107 
 GDS: 107 
 Hb-A1c: 6,6% 
 BUN/Ur/Cr: 19/41/1,1 
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 Electrolytes: 
o Na: 132 
o K: 3,5 
o Cl: 98 
 Blood Gas Analysis: 
o pH: 7,550 
o pCO2: 25 
o pO2: 151 
o Bicarbonate (HCO3): 21,9 
o Total CO2: 22,7 
o Base excess (BE): 0,3 
o O2 Saturation: 100 
 
Sinus tachycardia was concluded on ECG 
examination. On radiologic/x-ray examination, the 
hospital radiologist concluded that there were 
infiltrates on the left lung and interpret the finding as 
left lung pneumonia. Treatment for this patient stated 
below: 
 Bed rest + head up 30 deg. 
 Injected Meropenem 1 gram/8hour IV 
 Injected Levofloksasin 750 mg/24hour IV 
 Injected Vitamin C 1 gram/12hour IV 
 Injected Metilprednisolon 125 mg/12hour IV 
 Injected Lovenox 0,6 ml/12hour SC 
 Injected Omeprazole 40 mg/12hour IV 
 Zinc 20 mg/12 hour orally 
 B Complex 1 tab/8hour orally 
 Oseltamifir 75 mg/12hour po 
 Hidroquinon 200 mg/12hour po 
 Hidonac 200 mg in Dextrose 5% in Water 
given in 2 hours/24hour IV 
 
This patient was admitted for 18 days and tested for 
COVID-19 every 7-day using the PCR examination 
method. On the first day, this patient consulted the 
anesthesia department for airway management by using 
an endotracheal tube (ETT) and mechanical ventilation, 
with SaO2 95%-96% with setting SIMV 14, PEEP 8. 
VT 450, PSup 15, I:P 1:2, FiO2 100%, and then changed 
into SIMV 12, PEEP 6. VT 450, PSup 15, I:P 1:2, FiO2 
100%. A high flow nasal cannula was used on the day-
xx for x days, with oxygen saturation 96%-98% with 
FiO2% 60%. On admission, this patient was monitored 
for his blood pressure, heart rate, heart rhythm as 
expressed on ECG, and oxygen saturation, which ranged 
from 100 to 110 in systolic and 68-70 for diastolic. Heart 
rates were ranged in 80-90bpm. During admission, this 
patient was afebrile upon examination and denies any 
episodes of fever. Any other adverse effects from 
medication nor any additional symptoms were denied by 
the patient. This patient confirmed COVID-19 negative 
on the 17th day since admission with PCR test, then 
transferred to a non-COVID-19 ward on the same day 





On admission, anamnesis, physical examination, and 
screening were done to this patient by the ER Adam 
Malik General Hospital triage and suspected with 
COVID-19 for its clinical appearance and radiology 
expertise’s result. Every patient who had Acute 
Respiratory Infections (ARI) and in the last 14 days 
before symptoms develops (1) had traveled or live in a 
country/territory of Indonesia that reports local 
transmission (2) or had any contact with 
probable/confirmed COVID-19 patients, and (3) People 
with severe upper airway infection/pneumonia requiring 
hospitalization and no other cause based on convincing 
clinical appearances are categorized as suspect 
patients6. WHO advises for screening on every patient 
who may have COVID-19 – by finding any upper 
respiratory tract viral infection non-specific signs and 
symptoms, such as fever, fatigue, cough (with or 
without sputum production), anorexia, malaise, muscle 
pain, sore throat, dyspnea, nasal congestion, or 
headache. Rarely, patients may also present with 
diarrhea, nausea, and vomiting (6). Patients also 
screened for any signs or symptoms for sepsis such as 
life-threatening organ dysfunction caused by a 
dysregulated host response to suspected or proven 
infection. This patient was then treated on the quarantine 
ward, whilst waiting for his COVID-19 test result, with 
complete monitoring for vital signs – which is important 
for any COVID-19 suspects since its variety in severity.  
In Indonesia, tracking every person who had 
close contact with the patient is also important, 
regulated in the Guidelines For Prevention And Control 
Coronavirus Disease (Covid-19) (Pendoman 
Pencegahan dan Pengendalian Coronavirus Disease 
(COVID-19); this patient was found positive, and the 
screening was done accordingly. For asymptomatic 
patients, every close contact was screened from any 
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history of contacting the patient since 2 days before and 
14 days after testing specimen; for symptomatic 
patients, 2 days before and 14 days after any sign or 
symptoms show was used (3, 6). 
The elderly and immunosuppressed may present 
with atypical symptoms. Symptoms due to physiologic 
adaptations of pregnancy or adverse pregnancy events, 
such as dyspnea, fever, GI symptoms, or fatigue, may 
overlap with COVID-19 symptoms (6). 
COVID-19 patients tend to have decreased 
leukocyte (white blood cells / WBC) level, C-Reactive 
Protein (CRP) level and increased aspartate 
aminotransferase (AST) level, alanine aminotransferase 
(ALT and LDH) level, as concluded by Ferrari et al (7). 
In this patient, the value of SGOT (ALT) 53 and SGPT 
(AST) 107 each – both increase remarkedly, so if Ferrari 
et al study was applied, the diagnosis/rapid examination 
measures/swab COVID-19 is likely to get a positive 
result (7). 
Give supplemental oxygen therapy immediately 
to patients with SARI (Severe Acute Respiratory 
Infection) and respiratory distress, hypoxemia, or shock 
and target SpO2> 94%. Adults with emergency signs 
(obstructed or absent breathing, severe respiratory 
distress, central cyanosis, shock, coma, or convulsions) 
should receive airway management and oxygen therapy 
during resuscitation to target SpO2≥ 94%. Initiate 
oxygen therapy at 5 L/min and titrate flow rates to reach 
target SpO2 ≥93%during resuscitation, or use a face 
mask with reservoir bag (at 10–15 L/min) if the patient 
in critical condition (6). 
Once the patient was stable, the target was >90% 
SpO2 in non-pregnant adults. All areas where patients 
with SARI are cared for should be equipped with pulse 
oximeters, functioning oxygen systems, and disposable, 
single-use, oxygen-delivering interfaces (nasal cannula, 
nasal prongs, simple face mask, and mask with reservoir 
bag). Patients hospitalized with COVID-19 require 
regular monitoring of vital signs and, where possible, 
utilization of medical early warning score (e.g. NEWS2) 
that facilitate early recognition and escalation of 
treatment of the deteriorating patient. Recognize severe 
hypoxemic respiratory failure when a patient with 
respiratory distress is failing to respond to standard 
oxygen therapy and prepare to provide advanced 
oxygen/ventilatory support WHO (6).  
Empiric therapy should be de-escalated based on 
microbiology results and clinical judgment. Treatment 
with Levofloxacin was done following the WHO 
guideline, as WHO states that empiric antimicrobials 
must be given to treat all likely pathogens causing SARI 
and sepsis as soon as possible, within one hour of initial 
assessment for patients with sepsis. Although the patient 
may be suspected to have COVID-19, administer 
appropriate empiric antimicrobials within one hour of 
identification of sepsis (4-7). 
Oseltamivir, as a neuraminidase inhibitor (NAI), 
was hypothesized to be effective against COVID-19, as 
Zhang et al. found that the active site of the Spike (S) 1 
Protein of SARS is similar to that of neuraminidase, 
despite no clinical data suggest that oseltamivir is 
effective in treating SARS-CoV (8). From the research 
conducted by Anatoly et al and Wessels et al, zinc 
supplementation is one of the best covid-19 treatment 
choices, as zinc (Zn2+) provides an inhibitory effect of 
RNA replication in covid-19 patients, and in general, 
COVID-19 patients suffer from Zinc deficiency (9,10). 
Moreover, chloroquine treatment is also considered to 
potentiate the therapeutic effects of zinc, and 
administration of zinc can reduce the incidence of 
cytokine storms, prevent secondary lung infections, 
maintain lung tissue barriers and prevent complications 




As of date, COVID-19 is a disease that has many 
appearances. Quick treatment and intervention which 
determined from many factors; various studies, medical 
disciplines, and current National Ministry of Health’s 
regulations and treatment choices, and the patient signs 
and symptoms, hopefully, benefit the patient and prevents 
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